Relief reports u.s. collaboration partner's emergency use authorization request for zyesami/rlf-100 (aviptadil) for patients with critical covid-19 with respiratory failure was declined by u.s. fda

Geneva, switzerland / accesswire / november 5, 2021 / relief therapeutics holding sa (six:rlf)(otcqb:rlftf) ("relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its u.s. collaboration partner, nrx pharmaceuticals, inc., (nasdaq: nrxp) ("nrx"), has issued a press release announcing that it was declined emergency use authorization (eua) by the u.s. food and drug administration (fda) for the use of iv aviptadil for the treatment of acute respiratory failure due to critical covid-19. the related nrx press release can be accessed through the following link.
NRXP Ratings Summary
NRXP Quant Ranking